Literature DB >> 27935520

Effect of fructose consumption on insulin sensitivity in nondiabetic subjects: a systematic review and meta-analysis of diet-intervention trials.

Kasper W Ter Horst1, Merle R Schene2, Rebecca Holman3, Johannes A Romijn4, Mireille J Serlie2.   

Abstract

BACKGROUND: High fructose consumption has been suggested to contribute to several features of metabolic syndrome including insulin resistance, but to our knowledge, no previous meta-analyses have investigated the effect of fructose on insulin sensitivity in nondiabetic subjects.
OBJECTIVE: We performed a systematic review and meta-analysis of controlled diet-intervention studies in nondiabetic subjects to determine the effect of fructose on insulin sensitivity.
DESIGN: We searched MEDLINE, EMBASE, and the Cochrane Library for relevant trials on the basis of predetermined eligibility criteria. Two investigators independently performed the study selection, quality assessment, and data extraction. Results were pooled with the use of the generic inverse-variance method with random effects weighting and were expressed as mean differences (MDs) or standardized mean differences (SMDs) with 95% CIs.
RESULTS: Twenty-nine articles that described 46 comparisons in 1005 normal-weight and overweight or obese participants met the eligibility criteria. An energy-matched (isocaloric) exchange of dietary carbohydrates by fructose promoted hepatic insulin resistance (SMD: 0.47; 95% CI: 0.03, 0.91; P = 0.04) but had no effect on fasting plasma insulin concentrations (MD: -0.79 pmol/L; 95% CI: -6.41, 4.84 pmol/L; P = 0.78), the homeostasis model assessment of insulin resistance (HOMA-IR) (MD: 0.13; 95% CI: -0.07, 0.34; P = 0.21), or glucose disposal rates under euglycemic hyperinsulinemic clamp conditions (SMD: 0.00; 95% CI: 20.41, 0.41; P = 1.00). Hypercaloric fructose (∼25% excess of energy compared with that of the weight-maintenance control diet) raised fasting plasma insulin concentrations (MD: 3.38 pmol/L; 95% CI: 0.03, 6.73 pmol/L; P < 0.05) and induced hepatic insulin resistance (SMD: 0.77; 95% CI: 0.28, 1.26; P < 0.01) without affecting the HOMA-IR (MD: 0.18; 95% CI: -0.02, 0.39; P = 0.08) or glucose disposal rates (SMD: 0.10; 95% CI: -0.21, 0.40; P = 0.54). Results may have been limited by the low quality, small sample size, and short duration (mostly <60 d) of included trials.
CONCLUSIONS: Short-term fructose consumption, in isocaloric exchange or in hypercaloric supplementation, promotes the development of hepatic insulin resistance in nondiabetic adults without affecting peripheral or muscle insulin sensitivity. Larger and longer-term studies are needed to assess whether real-world fructose consumption has adverse effects on insulin sensitivity and long-term outcomes.
© 2016 American Society for Nutrition.

Entities:  

Keywords:  fructose; glucose clamp; glucose disposal; insulin; insulin resistance; meta-analysis

Mesh:

Substances:

Year:  2016        PMID: 27935520     DOI: 10.3945/ajcn.116.137786

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  26 in total

Review 1.  Fructose and hepatic insulin resistance.

Authors:  Samir Softic; Kimber L Stanhope; Jeremie Boucher; Senad Divanovic; Miguel A Lanaspa; Richard J Johnson; C Ronald Kahn
Journal:  Crit Rev Clin Lab Sci       Date:  2020-01-14       Impact factor: 6.250

2.  Tolerable upper intake level for dietary sugars.

Authors:  Dominique Turck; Torsten Bohn; Jacqueline Castenmiller; Stefaan de Henauw; Karen Ildico Hirsch-Ernst; Helle Katrine Knutsen; Alexander Maciuk; Inge Mangelsdorf; Harry J McArdle; Androniki Naska; Carmen Peláez; Kristina Pentieva; Alfonso Siani; Frank Thies; Sophia Tsabouri; Roger Adan; Pauline Emmett; Carlo Galli; Mathilde Kersting; Paula Moynihan; Luc Tappy; Laura Ciccolallo; Agnès de Sesmaisons-Lecarré; Lucia Fabiani; Zsuzsanna Horvath; Laura Martino; Irene Muñoz Guajardo; Silvia Valtueña Martínez; Marco Vinceti
Journal:  EFSA J       Date:  2022-02-28

Review 3.  Molecular aspects of fructose metabolism and metabolic disease.

Authors:  Mark A Herman; Morris J Birnbaum
Journal:  Cell Metab       Date:  2021-10-06       Impact factor: 27.287

Review 4.  Fructose metabolism and metabolic disease.

Authors:  Sarah A Hannou; Danielle E Haslam; Nicola M McKeown; Mark A Herman
Journal:  J Clin Invest       Date:  2018-02-01       Impact factor: 14.808

5.  Effects of stevia on synaptic plasticity and NADPH oxidase level of CNS in conditions of metabolic disorders caused by fructose.

Authors:  V A Chavushyan; K V Simonyan; R M Simonyan; A S Isoyan; G M Simonyan; M A Babakhanyan; L E Hovhannisyian; Kh H Nahapetyan; L G Avetisyan; M A Simonyan
Journal:  BMC Complement Altern Med       Date:  2017-12-19       Impact factor: 3.659

6.  Engineering digital biomarkers of interstitial glucose from noninvasive smartwatches.

Authors:  Brinnae Bent; Peter J Cho; Maria Henriquez; April Wittmann; Connie Thacker; Mark Feinglos; Matthew J Crowley; Jessilyn P Dunn
Journal:  NPJ Digit Med       Date:  2021-06-02

7.  [Is There an Effect of Dietary Fructose on Development and Prognosis of Chronic Diseases?]

Authors:  Armağan Aytuğ Yürük; Reyhan Nergiz-Ünal
Journal:  Florence Nightingale Hemsire Derg       Date:  2019-02-01

8.  Relevance of fructose intake in adolescence for fatty liver indices in young adulthood.

Authors:  Ines Perrar; Anette E Buyken; Katharina J Penczynski; Thomas Remer; Gunter G Kuhnle; Christian Herder; Michael Roden; Karen Della Corte; Ute Nöthlings; Ute Alexy
Journal:  Eur J Nutr       Date:  2021-01-19       Impact factor: 5.614

9.  Maternal dietary free or bound fructose diversely influence developmental programming of lipogenesis.

Authors:  Armagan Aytug Yuruk; Reyhan Nergiz-Unal
Journal:  Lipids Health Dis       Date:  2017-12-01       Impact factor: 3.876

10.  The FGF21 response to fructose predicts metabolic health and persists after bariatric surgery in obese humans.

Authors:  Kasper W Ter Horst; Pim W Gilijamse; Ahmet Demirkiran; Bart A van Wagensveld; Mariette T Ackermans; Joanne Verheij; Johannes A Romijn; Max Nieuwdorp; Eleftheria Maratos-Flier; Mark A Herman; Mireille J Serlie
Journal:  Mol Metab       Date:  2017-09-04       Impact factor: 7.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.